InVision Precision Cardiac Amyloid vs cV4 Diagnostic Ultrasound System
AI Verdict
Choose InVision Precision Cardiac Amyloid if…
Choose InVision Precision Cardiac Amyloid if your primary objective is to enhance the early and accurate detection of cardiac amyloidosis within your existing echocardiography workflow. This AI-powered software is specifically designed to analyze transthoracic echocardiogram studies, aiding clinicians in diagnosing and assessing patients with heart failure symptoms for both AL and ATTR types of the disease.
View InVision Precision Cardiac Amyloid →Choose cV4 Diagnostic Ultrasound System if…
Choose the Samsung Medison cV4 Diagnostic Ultrasound System if your facility requires a versatile, AI-enabled hardware ultrasound solution for a broad spectrum of diagnostic applications across multiple specialties. This system offers advanced imaging quality and AI-powered features for areas such as maternal-fetal medicine, obstetrics & gynecology, and general radiology, while also providing robust data security and a silent, fanless operation.
View cV4 Diagnostic Ultrasound System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | InVision Precision Cardiac Amyloid | cV4 Diagnostic Ultrasound System |
|---|---|---|
| Deployment | Cloud or on-premise | On-premise |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
InVision Precision Cardiac AmyloidTool A, as a Software as a Medical Device (SaMD), is designed to integrate into existing clinical workflows for echocardiography labs, which generally implies lower friction for adoption and daily use. In contrast, Tool B is a physical hardware device, requiring new system learning and physical deployment, even with its own streamlined AI-powered workflows.
Clinical Value
InVision Precision Cardiac AmyloidTool A offers AI-powered detection of cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and reduction of misdiagnosis. Its evidence-based algorithm has been peer-reviewed and published in JAMA Cardiology, indicating significant and validated clinical impact on a critical condition.
Pricing & Value
InVision Precision Cardiac AmyloidTool A provides transparent, subscription-based pricing starting at an accessible $49/month, with enterprise options available, making its cost-effectiveness clear. Tool B requires contacting for pricing, which is typical for a capital expenditure hardware device but lacks transparency, making direct value comparison difficult.
Enterprise Readiness
InVision Precision Cardiac AmyloidBoth tools are FDA-cleared and HIPAA compliant, but Tool A's deployment as SaMD, integrated into existing workflows, along with explicit mention of enterprise pricing and volume discounts, suggests a more scalable and potentially smoother adoption for large healthcare systems. Tool B, while having robust cybersecurity for a hardware device, involves physical deployment which can be a larger hurdle for widespread enterprise rollout.
Innovation
cV4 Diagnostic Ultrasound SystemTool B demonstrates broader innovation with its 'world's first fanless design' for silent operation and extended lifespan, alongside multiple AI-powered assists (HeartAssistu2122, NerveTracku2122, BiometryAssistu2122, LaborAssistu2122) across diverse clinical applications. While Tool A offers significant, clinically validated AI innovation in a specific niche, Tool B's combined hardware and multi-application AI advancements are more expansive.
Support & Docs
cV4 Diagnostic Ultrasound SystemAs a product from Samsung Medison, a large and established medical device manufacturer, Tool B likely benefits from a comprehensive global support network, extensive documentation, and structured training resources. InVision Medical Technology, while offering contact options, appears to be a more specialized software company, and typically, larger hardware manufacturers have more extensive support infrastructure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | InVision Precision Cardiac Amyloid | cV4 Diagnostic Ultrasound System |
|---|---|---|
| Name | InVision Precision Cardiac Amyloid | cV4 Diagnostic Ultrasound System |
| Company | InVision Medical Technology Corporation | Samsung Medison Co. |
| Description | AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes. | The Samsung Medison cV4 is an AI-enabled, fanless diagnostic ultrasound system offering advanced imaging, streamlined workflows, and robust data security for diverse clinical applications. |
| Primary Clinical Focus | Cardiac Amyloidosis detection via echocardiography | Diagnostic ultrasound for diverse clinical applications (Cardiology, OB/GYN, Radiology) |
| Key AI Features | AI-powered detection of cardiac amyloidosis, evaluation of transthoracic echocardiogram studies, precise assessment of wall thickness. | AI-powered HeartAssistu2122, NerveTracku2122, BiometryAssistu2122, LaborAssistu2122 |
| Specialties | Cardiology, Radiology | Maternal-Fetal Medicine, Obstetrics & Gynecology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and cV4 Diagnostic Ultrasound System.
Frequently Asked Questions
More Comparisons
More matchups featuring InVision Precision Cardiac Amyloid or cV4 Diagnostic Ultrasound System
- cV4 Diagnostic Ultrasound System vs EchoNext
- InVision Precision Cardiac Amyloid vs EchoNext
- InVision Precision Cardiac Amyloid vs MAGNETOM Cima.X
- Cardiac CT Function Software Application vs cV4 Diagnostic Ultrasound System
- InVision Precision Cardiac Amyloid vs V7 Diagnostic Ultrasound System
- InVision Precision Cardiac Amyloid vs uPMR 790